Current Report Filing (8-k)
21 April 2022 - 6:12AM
Edgar (US Regulatory)
0001739104
false
0001739104
2022-04-19
2022-04-19
0001739104
us-gaap:CommonStockMember
2022-04-19
2022-04-19
0001739104
elan:TangiblePercentEquityUnitsMember
2022-04-19
2022-04-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): April 19,
2022
Elanco
Animal Health Incorporated
(Exact name of registrant as specified
in its charter)
Indiana | |
001-38661 | |
82-5497352 |
(State
or other jurisdiction
of incorporation) | |
(Commission
File Number) | |
(I.R.S. Employer Identification No.) |
2500 Innovation Way
Greenfield, Indiana (Address of principal executive offices)
| |
46140 (Zip
Code) |
Registrant’s telephone number, including area code: (877)
352-6261
Not Applicable
(Former Name or Address, if Changed Since Last
Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
| ¨ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
Common stock, no par value |
|
ELAN |
|
New York Stock Exchange |
5.00% Tangible Equity Units |
|
ELAT |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
¨ Emerging
growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 1.01 |
Entry into a Material Definitive Agreement. |
On April 19, 2022, Elanco Animal Health Incorporated (the “Company”),
Elanco US Inc. and certain subsidiaries of the Company entered into an incremental assumption agreement (the “Incremental Assumption
Agreement”) with Farm Credit Mid-America, PCA, as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent,
supplementing and amending the Company’s existing credit agreement (the “Credit Agreement”) dated as of August 1, 2020
relating to its senior secured credit facility. The Incremental Assumption Agreement provides for a new incremental term facility under
the Credit Agreement in an aggregate principal amount of $250,000,000, to be used to repay outstanding obligations under its revolving
facility under the Credit Agreement. The incremental term facility matures on April 19, 2029. The terms of the new incremental term facility,
including the interest rate and repayment terms, are generally consistent with the terms of the Company’s existing term loan facility
under the Credit Agreement.
The foregoing description of the Incremental Assumption Agreement does
not purport to be complete and is qualified in its entirety by reference to the full text of the Incremental Assumption Agreement, which
is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Item 2.03 |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The disclosure set forth under Item 1.01 above is incorporated by reference
herein.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Elanco Animal Health Incorporated |
|
|
Date: April 20, 2022 |
By: |
/s/ Todd Young |
|
|
Name: Todd Young |
|
|
Title: Executive Vice President and Chief Financial Officer |
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jul 2023 to Jul 2024